Production (Stage)
Inozyme Pharma, Inc.
INZY
$3.98
-$0.01-0.25%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -3.56% | -10.19% | 9.11% | -15.79% | -8.37% |
| Total Depreciation and Amortization | -0.56% | -9.23% | 3.72% | 3.30% | -12.92% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -12.94% | 7.19% | 71.89% | 3,771.43% | 63.64% |
| Change in Net Operating Assets | -150.47% | 402.86% | -188.93% | 261.12% | -145.81% |
| Cash from Operations | -51.91% | 21.77% | -3.68% | 3.57% | -32.70% |
| Capital Expenditure | -- | -30.77% | -- | 100.00% | 69.52% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 117.92% | -33.83% | 31.12% | 70.88% | 263.80% |
| Cash from Investing | 118.16% | -33.87% | 31.05% | 71.41% | 260.65% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -11.63% | -97.55% | 2,197.60% | 188.05% | 893.75% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -11.63% | -97.55% | 2,197.60% | 188.05% | -98.73% |
| Foreign Exchange rate Adjustments | 150.00% | -300.00% | 0.00% | -110.00% | -92.54% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 236.38% | -137.40% | 273.48% | 61.45% | -13.51% |